PE20171110A1 - Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos - Google Patents

Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos

Info

Publication number
PE20171110A1
PE20171110A1 PE2017000467A PE2017000467A PE20171110A1 PE 20171110 A1 PE20171110 A1 PE 20171110A1 PE 2017000467 A PE2017000467 A PE 2017000467A PE 2017000467 A PE2017000467 A PE 2017000467A PE 20171110 A1 PE20171110 A1 PE 20171110A1
Authority
PE
Peru
Prior art keywords
methyl
dihydropyridin
oxo
halogen
alkyl
Prior art date
Application number
PE2017000467A
Other languages
English (en)
Inventor
Lena Elisabeth Ripa
Karolina Lawitz
Matti Juhani Lepisto
Martin Hemmerling
Karl Edman
Antonio Llinas
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54252264&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20171110(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20171110A1 publication Critical patent/PE20171110A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se refiere a un derivado de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo de formula I o una sal del mismo farmaceuticamente aceptable, donde R1 es halogeno, metilo o halometilo; R2 es halogeno; R3A, R3B y R3C son H, halogeno, halometilo o halometoxi; R4 es H, halogeno y metilo; R5 es metilo o etilo. Entre los compuestos preferidos tenemos: 2,2-difluoro-N-[(1R,2S)-3-metil-1-{[1-(1-metil-6-oxo-1,6-dihidropiridin-3-il)-1H-indazol-5-il]oxi}-1-fenilbutan-2-il]propanamida; 2,2,2-trifluoro-N-[(1R,2S)-3-metil-1-{[1-(1-metil-6-oxo-1,6-dihidropiridin-3-il)-1H-indazol-5-il]oxi}-1-fenilbutan-2-il]acetamida; entre otros. Tambien esta referida a una composicion farmaceutica. Dichos compuestos actuan sobre los receptores de glucocorticoides siendo utiles en el tratamiento de artritis reumatoidea, asma, entre otros
PE2017000467A 2014-09-26 2015-09-23 Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos PE20171110A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462055822P 2014-09-26 2014-09-26

Publications (1)

Publication Number Publication Date
PE20171110A1 true PE20171110A1 (es) 2017-08-07

Family

ID=54252264

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017000467A PE20171110A1 (es) 2014-09-26 2015-09-23 Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos

Country Status (30)

Country Link
US (1) US10196374B2 (es)
EP (1) EP3197878B1 (es)
JP (1) JP6430000B2 (es)
KR (1) KR101866706B1 (es)
CN (1) CN107001320B (es)
AP (1) AP2017009819A0 (es)
AR (1) AR105549A1 (es)
AU (1) AU2015323817B2 (es)
BR (1) BR112017006085B1 (es)
CA (1) CA2962312C (es)
CL (1) CL2017000715A1 (es)
CO (1) CO2017003955A2 (es)
CR (1) CR20170106A (es)
DO (1) DOP2017000064A (es)
EA (1) EA031945B1 (es)
ES (1) ES2751640T3 (es)
GT (1) GT201700058A (es)
IL (1) IL250886A0 (es)
MX (1) MX2017003697A (es)
NI (1) NI201700038A (es)
NZ (1) NZ730250A (es)
PE (1) PE20171110A1 (es)
PH (1) PH12017500533A1 (es)
SG (1) SG11201702225VA (es)
SV (1) SV2017005412A (es)
TN (1) TN2017000096A1 (es)
TW (1) TW201619146A (es)
UY (1) UY36327A (es)
WO (1) WO2016046260A1 (es)
ZA (1) ZA201702720B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017161518A1 (en) * 2016-03-23 2017-09-28 Astrazeneca Ab New physical form
TW201927769A (zh) 2017-12-18 2019-07-16 德商歌林達有限公司 經取代之吡咯啶醯胺ｉｉ
AR113967A1 (es) 2017-12-18 2020-07-01 Gruenenthal Gmbh Pirrolidinamidas i sustituidas
MX2021008364A (es) 2019-01-11 2021-08-05 Gruenenthal Gmbh Amidas de pirrolidina iii sustituidas.
ES2946888T3 (es) 2019-06-19 2023-07-27 Gruenenthal Gmbh Pirrolidina-amidas sustituidas IV
WO2020254552A2 (en) 2019-06-19 2020-12-24 Grünenthal GmbH Substituted pyrrolidine amides v
WO2021136429A1 (zh) * 2019-12-31 2021-07-08 南京明德新药研发有限公司 苯并吡唑类化合物
US20230265078A1 (en) 2020-07-09 2023-08-24 Gruenenthal Gmbh Substituted pyrrolidine amines and amides vi
WO2022012456A1 (en) * 2020-07-17 2022-01-20 Chengdu Easton Biopharmaceuticals Co., Ltd. Novel heterocyclic compounds as bet inhibitors
WO2023041695A1 (en) 2021-09-20 2023-03-23 Astrazeneca Ab Methods of treating inflammatory diseases with a selective glucocorticoid receptor modulator

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200700140A1 (ru) * 2004-07-16 2007-08-31 Янссен Фармацевтика Н.В. Димерные соединения пиперидина, пиперазина или морфолина или их семичленные аналоги, предназначенные для лечения нейродегенеративных нарушений
JO2754B1 (en) * 2006-12-21 2014-03-15 استرازينكا ايه بي Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders
US8211930B2 (en) * 2008-05-20 2012-07-03 Astrazeneca Ab Phenyl and benzodioxinyl substituted indazoles derivatives

Also Published As

Publication number Publication date
KR101866706B1 (ko) 2018-06-11
CR20170106A (es) 2017-09-01
NZ730250A (en) 2018-03-23
AU2015323817B2 (en) 2018-11-01
AU2015323817A1 (en) 2017-04-06
JP2017529369A (ja) 2017-10-05
TN2017000096A1 (en) 2018-07-04
ZA201702720B (en) 2019-06-26
CL2017000715A1 (es) 2017-11-10
WO2016046260A1 (en) 2016-03-31
CN107001320B (zh) 2019-09-20
BR112017006085B1 (pt) 2023-03-07
EA201790496A1 (ru) 2018-03-30
EP3197878B1 (en) 2019-07-24
EA031945B1 (ru) 2019-03-29
SV2017005412A (es) 2017-10-23
SG11201702225VA (en) 2017-04-27
CA2962312C (en) 2019-01-15
GT201700058A (es) 2019-08-12
ES2751640T3 (es) 2020-04-01
AR105549A1 (es) 2017-10-18
BR112017006085A2 (pt) 2017-12-19
DOP2017000064A (es) 2017-03-31
US10196374B2 (en) 2019-02-05
AP2017009819A0 (en) 2017-03-31
WO2016046260A8 (en) 2017-04-13
MX2017003697A (es) 2017-06-26
CA2962312A1 (en) 2016-03-31
EP3197878A1 (en) 2017-08-02
PH12017500533A1 (en) 2017-08-07
CO2017003955A2 (es) 2017-05-10
US20170298041A1 (en) 2017-10-19
JP6430000B2 (ja) 2018-11-28
CN107001320A (zh) 2017-08-01
UY36327A (es) 2016-04-01
NI201700038A (es) 2018-01-05
KR20170042785A (ko) 2017-04-19
IL250886A0 (en) 2017-04-30
TW201619146A (zh) 2016-06-01

Similar Documents

Publication Publication Date Title
PE20171110A1 (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
GT201600233A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
UY37435A (es) Pirrolidinas sustituidas y métodos para usarlas
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CL2017000240A1 (es) Compuestos activos hacia bromodominios
CL2016002573A1 (es) Compuesto de ciclopropanamina y sus usos.
UY36308A (es) Inhibidores de histona acetiltransferasas espirocíclicas (hat) y métodos para su uso
UY36056A (es) “compuestos de heteroarilo o arilo bicíclicos fusionados “.
CL2017000270A1 (es) Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias.
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
AR104984A1 (es) Compuestos selectivos para pyy y sus usos
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
BR112016025659A2 (pt) compostos, seus usos, e composições farmacêuticas para induzir condrogênese
CL2016000436A1 (es) Método para el tratamiento de la enfermedad fibrótica
DOP2017000107A (es) Diamino-quinoleina 2,4 sustituida como nuevos agentes anticancerigenos
UY36166A (es) Formas de sales de n—(cianometil)—4—(2—(4—morfolinofenilamino)pirimidin—4—il)benzamida, sus composiciones y su uso terapeutico
EP4289822A3 (en) Benzoimidazol-1,2-yl amides as kv7 channel activators
CL2016000597A1 (es) Derivados de desoxino jirimicina y sus métodos de uso.
AR096338A1 (es) (ciano-dimetil-metil)-isoxazoles y -[1,3,4]tiadiazoles
DOP2019000183A (es) Moduladores del receptor de estrógeno
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
CR20160527A (es) Derivados de carboxamida
ECSP18003372A (es) Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa
CL2016002779A1 (es) Composición para el cuidado de la piel
CL2016002267A1 (es) Ureas asimétricas p-sustituidas y usos médicos de las mismas